MEDVi Review
Best for: patients who want the option to switch between compounded and brand-name GLP-1 through one provider
MEDVi is a telehealth weight-loss platform offering compounded GLP-1 injections and tablets (semaglutide) as well as brand-name Wegovy and Zepbound through licensed US pharmacies. Medical treatment is delivered by OpenLoop Health clinicians and CareGLP Affiliated P.C.s.
Medium confidence · Last verified 2026-04-14 via websearch-multi-source · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
MEDVi is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
MEDVi prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Compounded GLP-1 Injection (first month) | compounded | $179 |
| Compounded GLP-1 Injection (refill) | compounded | $299 |
| Compounded GLP-1 Tablets | compounded | $249 |
| Starting | compounded | $349 |
✓ Pros
- •Both compounded and brand-name (Wegovy, Zepbound) GLP-1 options in one platform
- •Oral tablet and injectable formats
- •Named US pharmacy partners (Triad Rx, Precision Medicine, RedRock Pharmacy, Beaker Pharmacy & Compounding)
- •Clinical oversight through OpenLoop Health provider network and CareGLP Affiliated P.C.s
- •Direct-to-home shipping with 24/7 support
✗ Cons
- •Refill price for compounded GLP-1 injection ($299) steps up significantly from $179 first-month offer
- •Not available in Mississippi or North Dakota (telehealth regulation constraints)
- •Alabama and California patients can only receive injectable formats, not tablets, per state law
- •Kansas, Indiana, New Mexico, Oklahoma, and West Virginia require a synchronous provider visit before prescribing
- •No LegitScript or PCAB certification disclosed on the site
Ready to start with MEDVi?
Starting at $179/month. See current pricing and start your free consultation.
Sources & methodology
Our MEDVi review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to MEDVi
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with MEDVi?
Starting at $179/month. See current pricing and start your free consultation.